Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment is drawing significant interest across the industry.
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Ottawa's Olympic athletes touch down to a hero's welcome
- South Portland hoping to buy Walgreens as site for police station
- Garrett Nussmeier makes his case to be QB2 in the 2026 NFL Draft
- Lindsey Vonn Confesses to Harsh Truth Following Homecoming After Olympics Crash
Source: Original →